ACM
BBIO icon

ADAR1 Capital Management’s BridgeBio Pharma BBIO Stock Holding History

ADAR1 Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$30.4K – 290
2024
Q2 		$30.4K Hold
1,200
– – 0.01% 205
2024
Q1 		$37.1K Buy
+1,200
New +$40.8K 0.01% 197

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

ADAR1 Capital Management's BBIO Position: Q2 2026 in Review

ADAR1 Capital Management increased its BridgeBio Pharma (BBIO) stake by 87% in Q2 2026, buying an estimated $5.77M and bringing the position to 176,689 shares worth $13.2M. The position accounts for 0.6% of the portfolio, ranked #41.

ADAR1 Capital Management first reported a position in BBIO in Q4 2023 and has held it in 11 quarters since. The position peaked at $36.9M in Q3 2024. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • ADAR1 Capital Management held 176,689 shares of BridgeBio Pharma worth $13.2M as of Q2 2026.
  • ADAR1 Capital Management bought 82,397 BridgeBio Pharma shares in Q2 2026, an estimated $5.77M.
  • BridgeBio Pharma made up 0.6% of ADAR1 Capital Management's portfolio in Q2 2026, its #41 holding.
  • ADAR1 Capital Management first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 11 quarters since.
  • ADAR1 Capital Management's BridgeBio Pharma position peaked at $36.9M in Q3 2024.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.